179
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
203
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium
valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.
Cochrane Database Syst Rev. 2013 Jun 24;6. Review.
204
Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur)
is an effective preventive treatment for migraine. Neurology. 2004 Dec 28;63(12):2240-4.
205
Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Heada-
che. 1997;37 Suppl 1:S33-41. Review.
206
Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral
zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-
group, double-blind, placebo-controlled study. Headache. 2004 Feb;44(2):120-30.
207
Loder E. Naratriptan in the prophylaxis of cluster headache. Headache. 2002
Jan;42(1):56-7.
208
Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, Zhu Y, Massing MW, Fang Y. A randomized,
one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combinati-
on of flunarizine and topiramate in migraine prophylaxis. Pain Med. 2012 Jan;13(1):80-6.
209
Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug
responses? A meta-analytic comparison of topiramate-related adverse drug reactions in
epilepsy and migraine. Clin Pharmacol Ther. 2009 Mar;85(3):283-8.
210
MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B, Pawsey S. Safety and
tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009
Oct;49(9):1298-314.
211
MacGregor EA, Victor TW, Hu X, Xiang Q, Puenpatom RA, Chen W, Campbell JC. Characte-
ristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the
usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010
Apr;50(4):528-38.
212
MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treat-
ment of migraine. Cephalalgia. 1993 Apr;13(2):124-7.
213
MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose
riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-
controlled trial. J Child Neurol. 2008 Nov;23(11):1300-4.
214
Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J. Occipital nerve
stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet
Neurol. 2007 Apr;6(4):314-21.
215
Magis D, Sava S, D Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of trans-
cutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly(R) device in headache
treatment: a survey of 2,313 headache sufferers in the general population. J Headache
Pain. 2013 Dec 1;14(1):95.
216
Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and
feverfew for migraine prophylaxis: a randomized trial. Headache. 2004 Oct;44(9):885-90.